Skip to content
How It Works
Explore
Resources Ask a Question
Who It's For
Patients
Decode results, prep for appointments, weigh options.
Caregivers & advocates
Carry the research load for someone you love.
Providers & clinicians
Resources for patients in your practice.
Log In Ask a Question
PubMed This is a summary of 20 peer-reviewed journal articles Updated
Ophthalmology

The Progression of Vision Loss in Choroideremia

At a Glance

Vision loss in Choroideremia is a slow, progressive process that begins with night blindness in childhood. As patients reach their 20s and 30s, side vision diminishes, causing tunnel vision. Central, high-detail vision is usually preserved the longest, often lasting into a patient's 40s or 50s.

Choroideremia (CHM) does not happen all at once. It is a slow, progressive condition that typically follows a centripetal pattern—meaning it begins at the edges of your vision and moves steadily toward the center [1][2]. Because the change is gradual, many patients adapt to their vision loss without realizing how much has changed until they encounter a challenging environment, such as a dimly lit restaurant or a crowded sidewalk.

The First Sign: Night Blindness

For most males with CHM, the very first symptom is nyctalopia, or night blindness [3][2]. This often begins in childhood or the early teenage years [4].

  • How it feels: You may notice that it takes much longer for your eyes to “adjust” when coming inside from the sun.
  • Real-world impact: In daily life, this often manifests as difficulty seeing the steps in a dark movie theater, trouble navigating a backyard at dusk, or a general fear of walking in unfamiliar, poorly lit areas. You might find yourself “freezing” when lights go out or needing a flashlight even in moderately dim settings [5][6].

The Narrowing World: Peripheral Vision Loss

As the disease progresses through your 20s and 30s, the peripheral vision (your side vision) begins to constrict [3][7]. This is caused by the gradual loss of rod photoreceptors, the cells responsible for side vision and seeing in low light [4][8].

  • The “Tunnel” Effect: You may start to experience “tunnel vision,” where you can see clearly what is right in front of you, but objects to the side seem to disappear.
  • Mobility Challenges: This can lead to “clumsiness”—tripping over a dog on the floor, bumping your shoulder into a doorframe, or failing to see a curb. These are not signs of being uncoordinated; they are signs that your side-vision “early warning system” is diminishing [6][9].

The Question of Driving

As peripheral and night vision decline, driving safely—especially at night, in bad weather, or at high speeds—becomes a major safety concern. Many patients eventually need to stop driving. Discussing legal vision requirements and safety with your doctor and a low-vision specialist early can help you plan for alternative transportation and preserve your independence safely [6].

Later Stages: Central and Color Vision

One of the most important things to know about CHM is that foveal vision—your central, high-detail vision—is usually the last to go [4][2].

  • Preservation: Most patients maintain the ability to read, recognize faces, and perform detailed work well into their 40s or 50s [4].
  • Color Vision: Changes in color perception often happen only as the degeneration reaches the very center of the retina [10].
  • The “Accelerated” Phase: Around ages 30 to 40, some patients notice a faster decline in their best-corrected visual acuity (how well they see with glasses), which marks the transition toward central involvement [11].

Symptoms in Female Carriers

While CHM primarily affects males, female carriers are not always “symptom-free.” Because of a genetic process where one X chromosome is randomly turned off in each cell, a carrier’s retina is a mosaic of healthy and affected cells [12][13].

  • The “Mosaic” Appearance: An eye doctor can often see a characteristic “moth-eaten” or granular pattern of pigment changes in a carrier’s eye, even if she feels she sees perfectly [13][14].
  • Spectrum of Symptoms: Most carriers have normal vision and are unaware of any issues [15]. However, some carriers experience mild night blindness or small “blind spots” in their periphery [16][17]. In rare cases, a carrier can experience progressive vision loss similar to that of a male patient [18][19]. Regardless of symptoms, carriers should have regular eye exams to monitor for any structural changes [20].

Common questions in this guide

What is the first sign of Choroideremia?
The earliest symptom of Choroideremia is usually night blindness, also known as nyctalopia. This often begins in childhood or early teenage years, making it difficult to adjust to dim lighting or see in the dark.
Will I lose all my vision with Choroideremia?
Choroideremia is a progressive condition, but central, detailed vision is usually preserved the longest. Most patients maintain the ability to read and recognize faces well into their 40s or 50s before central vision is significantly affected.
Why am I becoming more clumsy or tripping more often?
As the disease progresses, you lose peripheral or side vision, creating a tunnel vision effect. This diminishes your side-vision warning system, making it harder to see obstacles like curbs or objects on the floor, which can lead to tripping.
Can female carriers of Choroideremia have vision symptoms?
Yes, while most female carriers do not have noticeable symptoms, some can experience mild night blindness or peripheral blind spots. All carriers should have regular eye exams to monitor for any structural changes in the retina.
How does Choroideremia affect my ability to drive?
As night vision and peripheral vision decline, driving safely—especially at night or in bad weather—becomes increasingly difficult. You should discuss your state's legal vision requirements and driving safety with your eye doctor early on to plan for alternative transportation.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.What is the current size of my visual field in degrees, and how does this compare to a 'normal' range?
  2. 2.Based on my imaging, how close is the degeneration to my fovea (the center of my vision)?
  3. 3.Am I showing signs of rod dysfunction, and how will that affect my mobility in low light?
  4. 4.Should my female relatives have a fundus exam to check for the 'mosaic' pattern, even if they have no symptoms?
  5. 5.At what point should I consider a referral to a low-vision specialist or mobility trainer?

Questions For You

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

References

References (20)
  1. 1

    Choroideremia Gene Therapy.

    Lam BL, Davis JL, Gregori NZ

    International ophthalmology clinics 2021; (61(4)):185-193 doi:10.1097/IIO.0000000000000385.

    PMID: 34584056
  2. 2

    X-linked Choroideremia.

    Tsang SH, Sharma T

    Advances in experimental medicine and biology 2018; (1085()):37-42 doi:10.1007/978-3-319-95046-4_9.

    PMID: 30578482
  3. 3

    Next-generation sequencing-based clinical diagnosis of choroideremia and comprehensive mutational and clinical analyses.

    Gao FJ, Tian GH, Hu FY, et al.

    BMC ophthalmology 2020; (20(1)):212 doi:10.1186/s12886-020-01478-x.

    PMID: 32487042
  4. 4

    Natural History of the Central Structural Abnormalities in Choroideremia: A Prospective Cross-Sectional Study.

    Aleman TS, Han G, Serrano LW, et al.

    Ophthalmology 2017; (124(3)):359-373 doi:10.1016/j.ophtha.2016.10.022.

    PMID: 27986385
  5. 5

    Clinical Manifestations and Genetic Analysis of 5 Korean Choroideremia Patients Initially Diagnosed With Retinitis Pigmentosa.

    Kim JH, Han JW, Choi EW, et al.

    Journal of Korean medical science 2022; (37(3)):e5 doi:10.3346/jkms.2022.37.e5.

    PMID: 35040292
  6. 6

    Exploring the impact of Choroideremia on women with phenotypic and/or genotypic evidence of disease: insights from a global survey.

    Bonneau S, Kulbay M, Kahn-Ali S, Qian CX

    Ophthalmic genetics 2024; (45(5)):452-461 doi:10.1080/13816810.2024.2357705.

    PMID: 38847528
  7. 7

    CHM/REP1 Transcript Expression and Loss of Visual Function in Patients Affected by Choroideremia.

    Di Iorio V, Esposito G, De Falco F, et al.

    Investigative ophthalmology & visual science 2019; (60(5)):1547-1555 doi:10.1167/iovs.18-25501.

    PMID: 30995293
  8. 8

    THE NATURAL HISTORY OF FULL-FIELD STIMULUS THRESHOLD DECLINE IN CHOROIDEREMIA.

    Dimopoulos IS, Freund PR, Knowles JA, MacDonald IM

    Retina (Philadelphia, Pa.) 2018; (38(9)):1731-1742 doi:10.1097/IAE.0000000000001764.

    PMID: 28800019
  9. 9

    Patient experience in retinitis pigmentosa and Choroideremia- a concept elicitation study in 17 patients based on qualitative interviews.

    Rometsch E, Thuresson PO, Hurst N, et al.

    Orphanet journal of rare diseases 2025; (20(1)):418 doi:10.1186/s13023-025-03713-4.

    PMID: 40790755
  10. 10

    Functional Defects in Color Vision in Patients With Choroideremia.

    Jolly JK, Groppe M, Birks J, et al.

    American journal of ophthalmology 2015; (160(4)):822-31.e3.

    PMID: 26133251
  11. 11

    Bilateral visual acuity decline in males with choroideremia: a pooled, cross-sectional meta-analysis.

    Bozkaya D, Zou H, Lu C, et al.

    BMC ophthalmology 2022; (22(1)):29 doi:10.1186/s12886-022-02250-z.

    PMID: 35034620
  12. 12

    PERIPHERAL OPTICAL COHERENCE TOMOGRAPHY FINDINGS IN A CHOROIDEREMIA CARRIER.

    Corvi F, Corradetti G, Wong A, et al.

    Retinal cases & brief reports 2022; (16(6)):766-769 doi:10.1097/ICB.0000000000001109.

    PMID: 33394956
  13. 13

    PHENOTYPING CHOROIDEREMIA AND ITS CARRIER STATE WITH MULTIMODAL IMAGING TECHNIQUES.

    Ma KK, Lin J, Boudreault K, et al.

    Retinal cases & brief reports 2017; (11 Suppl 1()):S178-S181 doi:10.1097/ICB.0000000000000419.

    PMID: 27599108
  14. 14

    Autofluorescence in female carriers with choroideremia: A familial case with a novel mutation in the CHM gene.

    Ortiz-Ramirez GY, Villanueva-Mendoza C, Zenteno Ruiz JC, et al.

    Ophthalmic genetics 2020; (41(6)):625-628 doi:10.1080/13816810.2020.1810283.

    PMID: 32835561
  15. 15

    High-Resolution Retinal Imaging Reveals Preserved Cone Photoreceptor Density and Choroidal Thickness in Female Carriers of Choroideremia.

    Suzuki K, Gocho K, Akeo K, et al.

    Ophthalmic surgery, lasers & imaging retina 2019; (50(2)):76-85 doi:10.3928/23258160-20190129-03.

    PMID: 30768214
  16. 16

    Retinal Characteristics of Female Choroideremia Carriers: Multimodal Imaging, Microperimetry, and Genetics.

    Gocuk SA, Edwards TL, Jolly JK, et al.

    Ophthalmology. Retina 2024; (8(12)):1200-1210 doi:10.1016/j.oret.2024.06.011.

    PMID: 38936773
  17. 17

    Longitudinal and cross-sectional study of retinal phenotypes and visual function in choroideremia carriers: a new grading system.

    Han X, Yu Y, Ding J, et al.

    Eye and vision (London, England) 2026; (13(1)).

    PMID: 41731546
  18. 18

    Spectrum of Disease Severity and Phenotype in Choroideremia Carriers.

    Jauregui R, Park KS, Tanaka AJ, et al.

    American journal of ophthalmology 2019; (207()):77-86 doi:10.1016/j.ajo.2019.06.002.

    PMID: 31181178
  19. 19

    Clinical and Genetic Findings in Korean Patients with Choroideremia.

    Jo WG, Lee CS, Han J

    Korean journal of ophthalmology : KJO 2023; (37(4)):285-291 doi:10.3341/kjo.2023.0020.

    PMID: 37336512
  20. 20

    Longitudinal assessment of female carriers of choroideremia using multimodal retinal imaging.

    Gocuk SA, Ayton LN, Edwards TL, et al.

    The British journal of ophthalmology 2025; (109(2)):293-299 doi:10.1136/bjo-2024-325578.

    PMID: 39122355

This page explains the progression of Choroideremia vision loss for educational purposes only. Always consult a low-vision specialist or ophthalmologist to discuss your specific vision changes and mobility needs.

Get notified when new evidence is published on Choroideremia.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.